Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on July 26, 2019. The filing addresses a legal settlement regarding the company's product VIVITROL (naltrexone for extended-release injectable suspension).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a legal event rather than periodic financial performance.
Material Changes and Events
On July 26, 2019, Alkermes Pharma Ireland Limited (APIL) and Amneal Pharmaceuticals LLC entered into a Settlement and License Agreement to resolve an inter partes review (IPR) petition challenging the validity of U.S. Patent Number 7,919,499 (the "'499 Patent"). Key terms include:
- The parties agreed to file a joint motion to terminate the IPR.
- APIL granted Amneal a non-exclusive, non-transferable, royalty-free license under certain patents, including the '499 Patent.
- Amneal is permitted to market and sell a generic formulation of VIVITROL in the U.S. beginning in 2028 or earlier under certain circumstances.
- The '499 Patent is an Orange Book-listed patent that expires in 2029.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future earnings. The primary risk disclosed is the potential for generic competition for VIVITROL starting in 2028, which is earlier than the patent's 2029 expiration date, though the agreement specifies this is subject to certain circumstances.
Investor Verification Checklist
- Verify the specific "certain circumstances" that would allow Amneal to launch the generic product before 2028.
- Assess the impact of a 2028 generic entry on VIVITROL's projected revenue stream relative to the 2029 patent expiration.
- Confirm the scope of the "certain patents" included in the royalty-free license beyond the '499 Patent.
- Review subsequent filings for any updates on the joint motion to terminate the IPR.